Global Neurological Disorder Drugs
Market Report
2025
The global neurological disorder drugs market size will be USD 112584.7 million in 2025. Rising prevalence of neurological disorders such as Alzheimer's and Parkinson's is expected to boost sales to USD 182169.43 million by 2033, with a Compound Annual Growth Rate (CAGR) of 6.20% from 2025 to 2033.
The base year for the calculation is 2024. The historical will be 2021 to 2024. The year 2025 will be estimated one while the forecasted data will be from year 2025 to 2033. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Neurological Disorder Drugs Market Report 2025.
According to Cognitive Market Research, the global Neurological disorder drugs market size will be USD 112584.7 million in 2025. It will expand at a compound annual growth rate (CAGR) of 6.20% from 2025 to 2033.
2021 | 2025 | 2033 | CAGR | |
---|---|---|---|---|
Global Neurological Disorder Drugs Market Sales Revenue | $ 72.842 Million | $ 112585 Million | $ 182169 Million | 6.2% |
North America Neurological Disorder Drugs Market Sales Revenue | $ 28.2043 Million | $ 41656.3 Million | $ 61573.3 Million | 5% |
United States Neurological Disorder Drugs Market Sales Revenue | $ 20.7471 Million | $ 32866.9 Million | 121212 | 4.8% |
Canada Neurological Disorder Drugs Market Sales Revenue | $ 5.246 Million | $ 4998.76 Million | 121212 | 5.8% |
Mexico Neurological Disorder Drugs Market Sales Revenue | $ 2.2112 Million | $ 3790.73 Million | 121212 | 5.5% |
Europe Neurological Disorder Drugs Market Sales Revenue | $ 19.7401 Million | $ 426.88 Million | $ 49185.7 Million | 5.3% |
United Kingdom Neurological Disorder Drugs Market Sales Revenue | $ 3.3104 Million | $ 5485.13 Million | 121212 | 6.1% |
Germany Neurological Disorder Drugs Market Sales Revenue | $ 4.256 Million | $ 6464.61 Million | 121212 | 5.5% |
France Neurological Disorder Drugs Market Sales Revenue | $ 2.8228 Million | $ 3003.76 Million | 121212 | 4.5% |
Italy Neurological Disorder Drugs Market Sales Revenue | $ 1.9227 Million | $ 2807.86 Million | 121212 | 4.7% |
Russia Neurological Disorder Drugs Market Sales Revenue | $ 1.6187 Million | $ 5060.68 Million | 121212 | 4.3% |
Spain Neurological Disorder Drugs Market Sales Revenue | $ 1.1607 Million | $ 2677.26 Million | 121212 | 4.4% |
Sweden Neurological Disorder Drugs Market Sales Revenue | $ 0.908 Million | $ 1012.14 Million | 121212 | 5.4% |
Denmark Neurological Disorder Drugs Market Sales Revenue | $ 0.9278 Million | $ 685.64 Million | 121212 | 5.1% |
Switzerland Neurological Disorder Drugs Market Sales Revenue | $ 0.8291 Million | $ 489.74 Million | 121212 | 4.9% |
Luxembourg Neurological Disorder Drugs Market Sales Revenue | $ 0.2961 Million | $ 391.79 Million | 121212 | 5.6% |
Rest of Europe Neurological Disorder Drugs Market Sales Revenue | $ 1.6878 Million | $ 4570.94 Million | 121212 | 4% |
Asia Pacific Neurological Disorder Drugs Market Sales Revenue | $ 16.098 Million | $ 27020.3 Million | $ 53740 Million | 9% |
China Neurological Disorder Drugs Market Sales Revenue | $ 5.388 Million | $ 11348.5 Million | 121212 | 8.5% |
Japan Neurological Disorder Drugs Market Sales Revenue | $ 3.1504 Million | $ 3728.81 Million | 121212 | 7.5% |
India Neurological Disorder Drugs Market Sales Revenue | $ 1.9736 Million | $ 2702.03 Million | 121212 | 10.9% |
South Korea Neurological Disorder Drugs Market Sales Revenue | $ 1.4376 Million | $ 3242.44 Million | 121212 | 8.1% |
Australia Neurological Disorder Drugs Market Sales Revenue | $ 1.3136 Million | $ 1405.06 Million | 121212 | 8.3% |
Singapore Neurological Disorder Drugs Market Sales Revenue | $ 0.4668 Million | $ 540.41 Million | 121212 | 9.3% |
South East Asia Neurological Disorder Drugs Market Sales Revenue | $ 1.4875 Million | $ 1783.34 Million | 121212 | 9.8% |
Taiwan Neurological Disorder Drugs Market Sales Revenue | $ 0.4829 Million | $ 1053.79 Million | 121212 | 8.8% |
Rest of APAC Neurological Disorder Drugs Market Sales Revenue | $ 0.3976 Million | $ 1215.91 Million | 121212 | 8.8% |
South America Neurological Disorder Drugs Market Sales Revenue | $ 3.7805 Million | $ 4278.22 Million | $ 7104.6 Million | 5.3% |
Brazil Neurological Disorder Drugs Market Sales Revenue | $ 1.5591 Million | $ 1831.08 Million | 121212 | 7.1% |
Argentina Neurological Disorder Drugs Market Sales Revenue | $ 0.688 Million | $ 718.74 Million | 121212 | 7.4% |
Colombia Neurological Disorder Drugs Market Sales Revenue | $ 0.5504 Million | $ 380.76 Million | 121212 | 6.3% |
Peru Neurological Disorder Drugs Market Sales Revenue | $ 0.3191 Million | $ 350.81 Million | 121212 | 6.7% |
Chile Neurological Disorder Drugs Market Sales Revenue | $ 0.3195 Million | $ 308.03 Million | 121212 | 6.8% |
Rest of South America Neurological Disorder Drugs Market Sales Revenue | $ 0.3444 Million | $ 688.79 Million | 121212 | 5.6% |
Middle East Neurological Disorder Drugs Market Sales Revenue | $ 3.0594 Million | $ 4503.39 Million | $ 7560 Million | 6.7% |
Saudi Arabia Neurological Disorder Drugs Market Sales Revenue | $ 1.2011 Million | $ 1585.19 Million | 121212 | 7% |
Turkey Neurological Disorder Drugs Market Sales Revenue | $ 0.5752 Million | $ 360.27 Million | 121212 | 7.3% |
UAE Neurological Disorder Drugs Market Sales Revenue | $ 0.4791 Million | $ 927.7 Million | 121212 | 7.2% |
Egypt Neurological Disorder Drugs Market Sales Revenue | $ 0.4283 Million | $ 270.2 Million | 121212 | 6.5% |
Qatar Neurological Disorder Drugs Market Sales Revenue | $ 0.1603 Million | $ 360.27 Million | 121212 | 6.2% |
Rest of Middle East Neurological Disorder Drugs Market Sales Revenue | $ 0.2154 Million | $ 999.75 Million | 121212 | 5.9% |
Africa Neurological Disorder Drugs Market Sales Revenue | $ 1.9594 Million | $ 2476.86 Million | $ 3005.8 Million | 2.4% |
Nigeria Neurological Disorder Drugs Market Sales Revenue | $ 0.5996 Million | $ 198.15 Million | 121212 | 2.6% |
South Africa Neurological Disorder Drugs Market Sales Revenue | $ 0.7563 Million | $ 871.86 Million | 121212 | 3.3% |
Rest of Africa Neurological Disorder Drugs Market Sales Revenue | $ 0.6035 Million | $ 1406.86 Million | 121212 | 1.6% |
Base Year | 2024 |
Historical Data Time Period | 2021-2024 |
Forecast Period | 2025-2033 |
Market Split by Disorder Type |
|
Market Split by Drug Class |
|
Market Split by Distribution Channel |
|
Market Split by Drug Formulation |
|
Market Split by End User |
|
Market Split by Patient Age Group |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
|
Report scope is customizable as we have a huge database of Neurological Disorder Drugs industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Neurological Disorder Drugs Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
The Neurological disorder drugs are pharmaceutical formulations designed to prevent, manage, and treat disorders affecting the central and peripheral nervous systems. These disorders include a wide range of conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and migraine. Neurological disorder drugs include categories such as antiepileptics, analgesics, anti-Parkinson’s drugs, antipsychotics, and neuroprotective agents. The neurological disorder drugs market is experiencing significant growth due to the increasing prevalence of neurological conditions globally, driven by the aging population and changing lifestyle patterns. Advancements in drug discovery technologies, including gene therapy and precision medicine, are enhancing treatment efficacy and expanding the range of available therapies. Additionally, rising healthcare expenditure, increased government funding for neurological research, and growing patient awareness are contributing to market growth.
In March 2023, the development of an oral, brain-penetrant, dual inhibitor of TYK2 and JAK1 for treating neurological illnesses was announced by Biohaven Ltd., except for the China region. https://ir.biohaven.com/news-releases/news-release-details/biohaven-acquires-exclusive-license-oral-brain-penetrant-dual
The increasing prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy is a significant driver for the neurological disorder drugs market. As the global population ages, the incidence of these conditions is rising, necessitating effective treatment options. According to the World Health Organization (WHO), neurological disorders are a leading cause of disability and death worldwide. This growing burden has prompted pharmaceutical companies to focus on developing innovative drugs and therapies to address these conditions, further boosting market growth. For instance, in March 2023, Pfizer Inc. announced that ZAVZPRETTM (zavegepant), the calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the immediate treatment of migraine with or without aura in adults, has received approval from the United States FDA.
Significant advancements in drug discovery and development technologies are driving the neurological disorder drugs market. Techniques such as artificial intelligence (AI), machine learning, and genomics are enabling the identification of novel drug targets and speeding up the drug development process. Moreover, innovations in biomarker research and precision medicine are paving the way for more effective and personalized treatments. These advancements not only enhance treatment outcomes but also reduce the time and cost associated with bringing new drugs to market, contributing to the overall growth of the industry.
The high cost associated with neurological disorder drugs poses a major restraint to market growth. Many advanced therapies, including biologics and gene therapies, come with a high price tag, making them unaffordable for a significant portion of the population. Additionally, the long duration and complexity of clinical trials for neurological disorder drugs add to the overall cost. Limited insurance coverage and high out-of-pocket expenses in some regions further restrict patient access to these critical treatments, hindering market expansion despite the increasing demand for innovative therapies.
The growing adoption of gene therapy and personalized medicine is emerging as a transformative trend in the neurological disorder drugs market. Gene therapies offer targeted treatments that address the root cause of neurological disorders at the genetic level, providing long-term benefits. Personalized medicine, which tailors treatments based on a patient’s genetic makeup and disease profile, is enhancing treatment efficacy and minimizing side effects. As these technologies gain momentum, they are expected to revolutionize the treatment landscape for neurological disorders, offering hope for better outcomes and improved quality of life.
There is a notable increase in investment in research and development (R&D) activities focused on developing novel therapies for neurological disorders. Pharmaceutical companies and research institutions are collaborating to explore innovative approaches such as stem cell therapy, neuroprotective agents, and monoclonal antibodies. These investments are aimed at addressing the unmet needs of patients and enhancing the effectiveness of existing treatment options. As a result, the influx of new therapies entering clinical trials and subsequent approvals is expected to drive sustained growth in the neurological disorder drugs market.
We have various report editions of Neurological Disorder Drugs Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.
The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.
Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.
Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.
Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.
The neurological disorder drugs market is highly competitive, with several global pharmaceutical companies actively developing and commercializing a wide range of therapies. Leading players such as Biogen Inc., Novartis AG, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., and GlaxoSmithKline plc dominate the market with established portfolios addressing various neurological conditions. These companies are heavily investing in research and development (R&D) to introduce innovative therapies, including biologics, gene therapies, and personalized medicine, to enhance treatment efficacy.
In March 2023, Acadia Pharmaceuticals Inc. announced that the United States FDA had approved DAYBUE (trofinetide) for treating Rett syndrome in adult and pediatric patients two years of age and older. In March 2022, AbbVie Inc. announced that it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A). https://news.abbvie.com/2022-03-01-AbbVie-Acquires-Syndesi-Therapeutics,-Strengthening-Neuroscience-Portfolio
Top Companies Market Share in Neurological Disorder Drugs Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
According to Cognitive Market Research, North America dominates the neurological disorder drugs market due to its advanced healthcare infrastructure, high healthcare expenditure, and strong presence of leading pharmaceutical companies. The region has a high prevalence of neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis, driving demand for effective treatments. Additionally, significant investments in research and development (R&D) and government funding for neurological research contribute to market growth.
Asia-Pacific is the fastest-growing region in the neurological disorder drugs market due to its rapidly aging population, increasing prevalence of neurological disorders, and improving healthcare infrastructure. Rising awareness about neurological conditions and growing access to advanced treatment options are driving demand in the region. Additionally, increased government investments in healthcare and pharmaceutical research, along with a growing number of clinical trials, are contributing to market expansion.
The current report Scope analyzes Neurological Disorder Drugs Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
According to Cognitive Market Research, the global Neurological disorder drugs market size was estimated at USD 43521.6 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 41656.34 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2025 to 2033.
According to Cognitive Market Research, the US had a major share in the Neurological disorder drugs market with a market size of USD 32866.85 million in 2025 and is projected to grow at a CAGR of 4.8% during the forecast period. The U.S. Market's rising prevalence of conditions such as Alzheimer’s, Parkinson’s, and epilepsy.
The Canadian Neurological disorder drugsmarket had a market share of USD 4998.76 million in 2025 and is projected to grow at a CAGR of 5.8% during the forecast period. Canada’s rising prevalence of conditions such as Alzheimer’s, Parkinson’s, and epilepsy.
The Mexico Neurological disorder drugs market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 3790.73 million in 2025..
According to Cognitive Market Research, the global Neurological disorder drugs market size was estimated at USD 112584.7 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 32649.56 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2033.
The United Kingdom Neurological disorder drugs market had a market share of USD 5485.13 million in 2025 and is projected to grow at a CAGR of 6.1% during the forecast period. In the UK, Neurological disorder drugs sales witnessed an upswing due to growing elderly population prone to neurological conditions and increasing adoption of innovative therapies.
The France Neurological disorder drugs market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 3003.76 million in 2025.
According to Cognitive Market Research, the German Neurological disorder drugs market size was valued at USD 6464.61 million in 2025 and is projected to grow at a CAGR of 5.5% during the forecast period. In Germany, growing elderly population prone to neurological conditions and increasing adoption of innovative therapies
The Italy Neurological disorder drugs market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 2807.86 million in 2025.
The Russia Neurological disorder drugs market is projected to witness growth at a CAGR of 4.3% during the forecast period, with a market size of USD 5060.68 million in 2025
The Spain Neurological disorder drugs market is projected to witness growth at a CAGR of 4.4% during the forecast period with a market size of USD 2677.26 million in 2025
The Sweden Neurological disorder drugs market is projected to witness growth at a CAGR of 5.4% during the forecast period, with a market size of USD 1012.14 million in 2025.
The Denmark Neurological disorder drugs market is projected to witness growth at a CAGR of 5.1% during the forecast period, with a market size of USD 685.64 million in 2025
The SwitzerlandNeurological disorder drugs market is projected to witness growth at a CAGR of 4.9% during the forecast period, with a market size of USD 489.74 million in 2025.
The Luxembourg Neurological disorder drugs market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 391.79 million in 2025.
The Rest of Europe's Neurological disorder drugs market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 4570.94 million in 2025.
According to Cognitive Market Research, the global Neurological disorder drugs market size was estimated at USD 112584.7 Million, out of which APAC held the market share of around 23% of the global revenue with a market size of USD 27020.33 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.0% from 2025 to 2033.
According to Cognitive Market Research, the China Neurological disorder drugs market size was valued at USD 11348.54 million in 2025 and is projected to grow at a CAGR of 8.5% during the forecast period. Neurological disorder drugs surged in China due to rapid growth, driven by an increasing prevalence of neurological conditions, rising healthcare expenditure.
The Japan Neurological disorder drugs market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 3728.81 million in 2025
The South Korea Neurological disorder drugs market had a market share of USD 3242.44 million in 2025 and is projected to grow at a CAGR of 8.1% during the forecast period. India's rapid growth, driven by an increasing prevalence of neurological conditions, rising healthcare expenditure.
The IndianNeurological disorder drugs market is projected to witness growth at a CAGR of 10.9% during the forecast period, with a market size of USD 2702.03 million in 2025.
The Australian Neurological disorder drugs market is projected to witness growth at a CAGR of 8.3% during the forecast period, with a market size of USD 1405.06 million in 2025.
The Singapore Neurological disorder drugs market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 540.41 million in 2025.
The Taiwan Neurological disorder drugs market is projected to witness growth at a CAGR of 8.8% during the forecast period, with a market size of USD 1053.79 million in 2025.
The South East Asia Neurological disorder drugs market is projected to witness growth at a CAGR of 9.8%during the forecast period, with a market size of USD 1783.34 million in 2025.
The Rest of APAC Neurological disorder drugs market is projected to witness growth at a CAGR of 8.8% during the forecast period, with a market size of USD 1215.91 million in 2025.
According to Cognitive Market Research, the global Neurological disorder drugs market size was estimated at USD 112584.7 Million, out of which South America held the market share of around 5% of the global revenue with a market size of USD 4278.22 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2033.
According to Cognitive Market Research, the Brazil Neurological disorder drugs market size was valued at USD 1831.08 million in 2025 and is projected to grow at a CAGR of 7.1% during the forecast period. Neurological disorder drugs flourished in Brazil due to rising incidences of neurological disorders such as epilepsy, multiple sclerosis, and Alzheimer.
Argentina's Neurological disorder drugs market had a market share of USD 718.74 million in 2025 and is projected to grow at a CAGR of 7.4% during the forecast period. Argentina's rising incidences of neurological disorders such as epilepsy, multiple sclerosis, and Alzheimer.
Colombia Neurological disorder drugs market is projected to witness growth at a CAGR of 6.3% during the forecast period, with a market size of USD 380.76 million in 2025
Peru Neurological disorder drugs market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 350.81 million in 2025.
Chile Neurological disorder drugs market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 308.03 million in 2025
The Rest of South America's Neurological disorder drugs market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 688.79 million in 2025.
According to Cognitive Market Research, the global Neurological disorder drugs market size was estimated at USD 112584.7 Million, out of which the Middle East held the major market share of around 2% of the global revenue with a market size of USD 4503.39 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2033..
The Qatar Neurological disorder drugs market is projected to witness growth at a CAGR of 6.2% during the forecast period, with a market size of USD 360.27 million in 2025. Neurological disorder drugs sales flourish due to the increasing prevalence of conditions such as epilepsy, stroke, and multiple sclerosis.
The Saudi Arabia Neurological disorder drugs market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 1585.19 million in 2025.
The Turkey Neurological disorder drugs market is projected to witness growth at a CAGR of 7.3% during the forecast period, with a market size of USD 360.27 million in 2025. Neurological disorder drugs sales flourished in Turkey due to increasing prevalence of conditions such as epilepsy, stroke, and multiple sclerosis.
The UAE Neurological disorder drugs market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 927.70 million in 2025.
The Egypt Neurological disorder drugs market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 270.20 million in 2025.
The Rest of the Middle East Neurological disorder drugs market is projected to witness growth at a CAGR of 5.9% during the forecast period, with a market size of USD 999.75 million in 2025
According to Cognitive Market Research, the global Neurological disorder drugs market size was estimated at USD 112584.7 Million, out of which the Africa held the major market share of around 2% of the global revenue with a market size of USD 2476.86 million in 2025 and will grow at a compound annual growth rate (CAGR) of 2.4% from 2025 to 2033..
The Nigeria Neurological disorder drugs market is projected to witness growth at a CAGR of 2.6% during the forecast period, with a market size of USD 198.15 million in 2025. Neurological disorder drugs sales flourish due to the rising burden of conditions such as epilepsy, stroke, and neuroinfections.
The South Africa Neurological disorder drugs market is projected to witness growth at a CAGR of 3.3% during the forecast period, with a market size of USD 871.86 million in 2025.
The Rest of Africa Neurological disorder drugsmarket is projected to witness growth at a CAGR of 1.6% during the forecast period, with a market size of USD 1406.86 million in 2025.
Global Neurological Disorder Drugs Market Report 2025 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Neurological Disorder Drugs Industry growth. Neurological Disorder Drugs market has been segmented with the help of its Disorder Type, Drug Class Distribution Channel, and others. Neurological Disorder Drugs market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
How are Segments Performing in the Global Neurological disorder drugs Market?
According to Cognitive Market Research, Alzheimer’s disease drugs dominate the neurological disorder drugs market due to the high prevalence of the condition, especially among the aging population. As the leading cause of dementia, Alzheimer's disease affects millions worldwide, driving demand for effective treatments. Currently, available drugs primarily focus on managing symptoms and slowing disease progression, contributing to their widespread use. Continuous research and development (R&D) efforts aimed at discovering disease-modifying therapies are further strengthening this segment.
Parkinson’s disease drugs are the fastest-growing segment in the neurological disorder drugs market, driven by the rising incidence of the condition and advancements in treatment options. With increasing awareness and early diagnosis, the demand for effective therapies to manage motor and non-motor symptoms is growing rapidly. Innovations such as gene therapy and neuroprotective agents are revolutionizing Parkinson’s disease treatment, contributing to accelerated market growth.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Neurological Disorder Drugs Industry. Request a Free Sample PDF!
According to Cognitive Market Research, the Antiepileptic drugs (AEDs) dominate the neurological disorder drugs market due to their widespread use in managing epilepsy and related seizure disorders. These drugs effectively control abnormal brain activity and reduce seizure frequency, making them a primary treatment option. With a variety of first-line and second-line therapies available, antiepileptic drugs cater to different patient needs and treatment responses. Continuous advancements in AED formulations, such as extended-release and combination therapies, further strengthen this segment.
Antipsychotic drugs are the fastest-growing segment in the neurological disorder drugs market, driven by the increasing prevalence of psychiatric and neurological conditions such as schizophrenia, bipolar disorder, and dementia-related agitation. These drugs are essential in managing symptoms by modulating neurotransmitter activity, improving patient quality of life. Innovations in second-generation antipsychotics, offering fewer side effects and better tolerability, are boosting their adoption.
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
According to Cognitive Market Research, Hospital pharmacies dominate the neurological disorder drugs market due to the critical need for specialized care and immediate access to prescription medications in hospital settings. Patients with severe neurological conditions, such as epilepsy, stroke, and Parkinson’s disease, often require timely administration of medications, making hospital pharmacies the primary distribution channel. Additionally, hospital pharmacies offer advanced treatment options, including biologics and injectables, which are typically administered under medical supervision.
Online pharmacies are the fastest-growing segment in the neurological disorder drugs market, driven by the increasing adoption of e-commerce platforms and the growing preference for convenience. Patients with chronic neurological conditions benefit from the ease of home delivery and automated prescription refills, reducing the need for frequent visits to physical pharmacies. The COVID-19 pandemic further accelerated this trend, highlighting the importance of remote access to medications.
Senior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Conclusion
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Disclaimer:
Disorder Type | Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Epilepsy, Migraine, Stroke, Other Neurological Disorders |
Drug Class | Anticholinergic, Antiepileptic, Antipsychotic, Hypnotic & Sedatives, Analgesics, Antihypertensive, Anticoagulants, Others |
Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others |
Drug Formulation | Oral, Injectable, Topical, Others |
End User | Hospitals, Specialty Clinics, Homecare, Other |
Patient Age Group | Pediatric, Adult, Geriatric |
List of Competitors | Sun Pharmaceutical Industries Ltd., Novartis AG, Biogen, F. Hoffmann-La Roche Ltd., Sanofi, Orion Corporation, AbbVie Inc., UCB S.A., Teva Pharmaceutical Industries Ltd. |
This chapter will help you gain GLOBAL Market Analysis of Neurological Disorder Drugs. Further deep in this chapter, you will be able to review Global Neurological Disorder Drugs Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
This chapter will help you gain North America Market Analysis of Neurological Disorder Drugs. Further deep in this chapter, you will be able to review North America Neurological Disorder Drugs Market Split by various segments and Country Split.
Chapter 2 North America Market Analysis
This chapter will help you gain Europe Market Analysis of Neurological Disorder Drugs. Further deep in this chapter, you will be able to review Europe Neurological Disorder Drugs Market Split by various segments and Country Split.
Chapter 3 Europe Market Analysis
This chapter will help you gain Asia Pacific Market Analysis of Neurological Disorder Drugs. Further deep in this chapter, you will be able to review Asia Pacific Neurological Disorder Drugs Market Split by various segments and Country Split.
Chapter 4 Asia Pacific Market Analysis
This chapter will help you gain South America Market Analysis of Neurological Disorder Drugs. Further deep in this chapter, you will be able to review South America Neurological Disorder Drugs Market Split by various segments and Country Split.
Chapter 5 South America Market Analysis
This chapter will help you gain Middle East Market Analysis of Neurological Disorder Drugs. Further deep in this chapter, you will be able to review Middle East Neurological Disorder Drugs Market Split by various segments and Country Split.
Chapter 6 Middle East Market Analysis
This chapter will help you gain Middle East Market Analysis of Neurological Disorder Drugs. Further deep in this chapter, you will be able to review Middle East Neurological Disorder Drugs Market Split by various segments and Country Split.
Chapter 7 Africa Market Analysis
This chapter provides an in-depth analysis of the market share among key competitors of Neurological Disorder Drugs. The analysis highlights each competitor's position in the market, growth trends, and financial performance, offering insights into competitive dynamics, and emerging players.
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
This chapter would comprehensively cover market drivers, trends, restraints, opportunities, and various in-depth analyses like industrial chain, PESTEL, Porter’s Five Forces, and ESG, among others. It would also include product life cycle, technological advancements, and patent insights.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Disorder Type Analysis 2019 -2031, will provide market size split by Disorder Type. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Disorder Type Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Drug Class Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by Distribution Channel Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 13 Market Split by Drug Formulation Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 14 Market Split by End User Analysis 2021 - 2033
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 15 Market Split by Patient Age Group Analysis 2021 - 2033
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Neurological Disorder Drugs market
Chapter 16 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Chapter 17 Research Methodology and Sources
Why Alzheimer’s Disease have a significant impact on Neurological Disorder Drugs market? |
What are the key factors affecting the Alzheimer’s Disease and Parkinson’s Disease of Neurological Disorder Drugs Market? |
What is the CAGR/Growth Rate of Anticholinergic during the forecast period? |
By type, which segment accounted for largest share of the global Neurological Disorder Drugs Market? |
Which region is expected to dominate the global Neurological Disorder Drugs Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|